>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: STX +13.7%, NEPT +13.7%, AA +3.7%, ( Cube Hydro Carolinas reaches agreement to acquire hydroelectric plants from Alcoa Power Generating)

M&A news:
  • RRD +5.7% (reports of RR Donnelley & Sons potential merger with Xerox's Copy unit)
  • XRX +2.3%
Select EU financial related names showing strength: DB +5.1%, BCS +4.6%, LYG +4.5%, SAN +4%, RBS +3.4%, ING+2.9%, HSBC +0.5%

Select metals/mining stocks trading higher: CLF +6.7%, MT +4.2%, FCX +3.9%, VALE +2.3%, SBGL +1.6%, RIO+1.6%, GFI +1.2%, BHP +1%

Select oil/gas related names showing strength: SDRL +4.9%, TOT +2.8%, MRO +2.7%, SWN +2.7%, RDS.A +1.7%,BP +1.5%

Other news:
  • SAGE +41.9% (announces positive top-line results from its Phase 2 clinical trial of SAGE-547)
  • JRJR +13.6% ( compliance plan was accepted by NYSE MKT relating to failure to timely file its Quarterly Report on Form 10-Q)
  • BAA +12.8% (reports Q2 operating results)
  • BDSI +11.2% ( secured preferred formulary status for BUNAVAIL on a 'significant' managed care plan )
  • CEL +8.4% (Company commenced legal actions against Golan Telecom, including a request for an interim injunction against the consummation of the Golan Telecom - Hot Mobile agreement)
  • MGT +7.4% (following late pullback -- released prelim proxy statement)
  • CASC +5.7% (Growth Equity Opportunities Fund discloses 8.3% active stake)
  • SHPG +5.2% (receives FDA approval for Xiidrag)
  • BLFS +5.1% (following Monday's 50%+ move higher)
  • WDC +4.1% (on STX guidance)
  • RLYP +3.7% (discloses new patient starts, outpatient prescriptions and units sold to hospitals/other institutions for June)
  • CLDX +3.1% (initiates Phase 1/2 clinical trial of new product candidate CDX-014 in advanced renal cell carcinoma)
  • REN +3% (following Monday's 50%+ move higher; also John C. Goff increases active stake to 9.9%)
  • STM +2.5% (in sympathy with STX)
  • GSS +2% ( Pre-commercial production has commenced at its Wassa Underground Mine in Ghana, as scheduled)
  • NTIP +1.4% ( discloses settlement of patent litigation with Alcatel-Lucent Entities and ALE)
  • UAL +1.4% (reported June 2016 operational results; expects Q2 passenger unit revenue to decline 6.50% to 6.75% YoY, citing several headwinds )
Analyst comments:
  • CHK +4.3% (upgraded to Neutral from Underweight at Piper Jaffray)
  • GFI +1.2% (upgraded to Neutral from Underweight at JP Morgan)
  • ORCL +1.0% (upgraded to Outperform from Market Perform at BMO Capital Markets)